Skip to main content
SpringerLink
Log in

Medical Therapy of Fistulizing Crohn’s Disease

  • Chapter
Inflammatory Bowel Disease and Familial Adenomatous Polyposis

  • 788 Accesses

Conclusion

Treatment of CD fistulizing Crohn’s disease requires a close collaboration between the gastroenterologist and the surgeon. Antibiotics and immunomodulators such as azathioprine/6-mercaptopurine or methotrexate, if the patient is AZA-6MP intolerant/resistant, should be given early in the disease. In the case of resistance to immunomodulators, infliximab is the treatment of choice. Short-term cyclosporine A or tacrolimus may be tried in patients who fail to respond to infliximab. Abscesses should always be drained by an expert surgeon.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Steinberg DM (1973) Abscess and fistulae in Crohn disease. Gut 14:865–869

    PubMed  CAS  Google Scholar 

  2. Rankin GB (1979) National cooperative Crohn’s disease study: extraintestinal manifestations and perianal complications. Gastroenterology 77:914–20

    PubMed  CAS  Google Scholar 

  3. Farmer RG (1975) Clinical patterns in Crohn’s disease: a statistical study of 615 patients. Gastroenterology 68:627–635

    PubMed  CAS  Google Scholar 

  4. Sachar DB, Bodian CA, Goldstein ES et al (2005) Is perianal Crohn’s disease associated with intestinal fistulization? Am J Gastroenterol 100(7):1547–1549

    Article  PubMed  Google Scholar 

  5. Bell SJ, Williams AB, Wiesel P, Wilkinson K, Cohen RCG, Kamm MA (2003) The clinical course of fistulating Crohn’s disease. Aliment Pharmacol Ther 17:1145–1151

    Article  PubMed  CAS  Google Scholar 

  6. Schwartz DA (2002) The Natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 122:875–880

    Article  PubMed  Google Scholar 

  7. Gray BK, Lockhartmummery HE, Morson BC (1965) Crohn’s disease of the anal region. Gut 6:515–524

    PubMed  CAS  Google Scholar 

  8. Hellers G, Bergstrand O, Ewerth S, Holmstrom B (1980) Occurrence in outcome after primary treatment of anal fistulae in Crohn’s disease. Gut 21:525–527

    PubMed  CAS  Google Scholar 

  9. Present DH (2000) How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 6:48–57

    Article  PubMed  CAS  Google Scholar 

  10. Judge TA, Lichtenstein GR (2004) Treatment of fistulizing Crohn’s disease. Gastroenterol Clin N Am 33:421–454

    Article  Google Scholar 

  11. Sparberg M, Kirsner JB (1966) Long-term corticosteroid therapy for enteritis: an analysis of 58 courses in 54 patients. Am J Dig Dis 11:865–880

    Article  PubMed  CAS  Google Scholar 

  12. Jones JH, Lennard-Jones JF (1966) Corticosteroids and corticotrophin in the treatment of Crohn’s disease. Gut 7:181–187

    PubMed  CAS  Google Scholar 

  13. Malchow H, Ewe J, Brandes W et al (1984) European cooperative Crohn’s disease study (ECCDS): results of drug treatment. Gastroenterology 86:249–266

    PubMed  CAS  Google Scholar 

  14. Agrawal A, Durrani S, Leiper K et al (2005) Effect of systemic corticosteroid therapy on risk for intraabdominal or pelvic abscess in non-operated Crohn’s disease. Clin Gastroenterol Hepatol 3:1215–1220

    Article  PubMed  CAS  Google Scholar 

  15. Present DH (2002) Urinary tract fistulae in Crohn’s disease: surgery versus medical therapy. Am J Gastroenterol 97:2165–2167

    Article  PubMed  Google Scholar 

  16. Ursing B, Kamme C (1975) Metronidazole for Crohn’s disease. Lancet 1:775–777

    Article  PubMed  CAS  Google Scholar 

  17. Bernstein LH, Frank MS, Brandt LJ, Boley SJ (1980) Metronidazole therapy for perineal Crohn’s disease with metronidazole. Gastroenterology 79:357–365

    PubMed  CAS  Google Scholar 

  18. Brandt LJ, Bernstein LH, Boley SJ, Frank MS (1982) Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology 83:383–387

    PubMed  CAS  Google Scholar 

  19. Jakobovits J, Schuster MM (1984) Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol 79:533–540

    PubMed  CAS  Google Scholar 

  20. Schneider MU, Laudage G, Guggenmoos-Holzma I, Riemann JF (1985) Metronidazol in der behandlung des morbus Crohn. Dtsch Med Wochenschr 110:1724–1930

    Article  PubMed  CAS  Google Scholar 

  21. Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr (2001) Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology 120:1640–1656

    Article  PubMed  CAS  Google Scholar 

  22. Duffy LF, Daum F, Fisher SE et al (1985) Peripheral neuropathy in Crohn’s disease patients treated with metronidazole. Gastroenterology 88:681–684

    PubMed  CAS  Google Scholar 

  23. Turunen U, Farkkila M, Seppala K (1989) Long-term treatment of peri-anal or fistulous Crohn’s disease with ciprofloxacin. Scan J Gastroenterol 24:144–148

    Google Scholar 

  24. Solomon M, McLeod R, O’Connor B et al (1993) Combination ciprofloxacin and medronidazole in severe perianal Crohn’s disease. Can J Gastroenterol 7:571–573

    Google Scholar 

  25. Present DH, Korelitz BI, Wisch N et al (1980) Treatment of Crohn’s disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 302:981–987

    Article  PubMed  CAS  Google Scholar 

  26. Korelitz BI, Present DH (1985) Favorable effect of 6-mercaptopurine on fistulae of Crohn’s disease. Dig Dis Sci 30:58–64

    Article  PubMed  CAS  Google Scholar 

  27. Pearson DC, May GR, Fick GH, Sutherland LR (1995) Azathioprine and 6-mercaptopurine in Crohn’s disease: a meta-analysis. Ann Intern Med 123:132–142

    PubMed  CAS  Google Scholar 

  28. Cuffari C, Hunt S, Bayless T (2001) Utilization of 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 48:642–646

    Article  PubMed  CAS  Google Scholar 

  29. Present DH, Meltzer SJ, Krumholtz MP et al (1989) 6-mercaptopurine in the management of inflammatory bowel disease: short and long-term toxicity. Ann Intern Med 111:641–649

    PubMed  CAS  Google Scholar 

  30. Mahadevan U, Marion JF, Present DH (2003) Fistula response to methotrexate in Crohn’s disease: a case series. Aliment Pharmacol Ther 18:1003–1008

    Article  PubMed  CAS  Google Scholar 

  31. Vandeputte L, D’Haens G, Baert F, Rutgeerts P (1999) Methotrexate in refractory Crohn’s disease. Inflamm Bowel Dis 5:11–15

    Article  PubMed  CAS  Google Scholar 

  32. Lemann M, Zenjari T, Bouhnik Y et al (2000) Methotrexate in Crohn’s disease: long-term efficacy and toxicity. Am J Gastroenterol 95:1730–1734

    PubMed  CAS  Google Scholar 

  33. Te HS, Schiano TD, Kuan SF et al (2000) Hepatic effect of long-term methotrexate use in treatment of inflammatory bowel disease. Am J Gastroenterol 95:3150–3156

    Article  PubMed  CAS  Google Scholar 

  34. Fukushima T, Sugita A, Masuzawa S et al (1989) Effects of cyclosporine A on active Crohn’s disease. Gastroenterol JPN 24:12–15

    PubMed  CAS  Google Scholar 

  35. Lichtiger S (1990) Cyclosporine therapy in inflammatory bowel disease: open-label experience. Mt Sinai J Med 57:315–319

    PubMed  CAS  Google Scholar 

  36. Hanauer SB, Smith MB (1993) Rapid closure of Crohn’s disease fistulae with continuous intravenous cyclosporine A. Am J Gastroenterol 88:646–649

    PubMed  CAS  Google Scholar 

  37. Present DH, Lichtiger S (1994) Efficacy of cyclosporine in treatment of fistula of Crohn’s disease. Dig Dis Sci 39:374–380

    Article  PubMed  CAS  Google Scholar 

  38. Markowitz J, Rosa J, Grancher K et al (1990) Longterm 6-mercaptopurine treatment in adolescents with Crohn’s disease. Gastroenterology 99:1347–1351

    PubMed  CAS  Google Scholar 

  39. Abreu-Martin M, Vasiliauskas E, Gaiennie J (1996) Continuous infusion cyclosporine is effective for severe acute Crohn’s disease: but for how long? Gastroenterology 110:A851

    Google Scholar 

  40. O’Neill J, Pathhmakanthan S, Goh J (1997) Cyclosporine A induces remission in fistulous Crohn’s disease but relapse occurs upon cessation of treatment. Gastroenterology 112:A1056

    Article  Google Scholar 

  41. Hinterleitner TA, Petritsch W, Aichbichler B et al (1997) Combination of cyclosporine, azathioprine and prednisolone for perianal fistulae in Crohn’s disease. Z Gastroenterol 35:603–608

    PubMed  CAS  Google Scholar 

  42. Egan LJ, Sandborn WJ, Tremaine WJ (1998) Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn’s disease with intravenous cyclosporine. Am J Gastroenterol 93:442–448

    Article  PubMed  CAS  Google Scholar 

  43. Gurudu SR, Griffel LH, Gialanella RJ, Das KM (1999) Cyclosporine therapy in inflammatory bowel disease: short-term and long-term results. J Clin Gastroenterol 29:151–154

    Article  PubMed  CAS  Google Scholar 

  44. Hinterleitner TA, Petritsch W, Aichbichler B, Fickert P, ranner G, Krejs GJ (1997) Combination of cyclosporine, azathioprine and prednisolone for perianal fistulae in Crohn’s disease. Z Gastroenterol 35:603–608

    PubMed  CAS  Google Scholar 

  45. Sandborn W (1995) A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1:48–63

    Article  Google Scholar 

  46. Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ (1999) Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn’s disease perianal fistulae. Inflamm Bowel Dis 5:239–245

    Article  PubMed  CAS  Google Scholar 

  47. Sandborn WJ (1997) Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn’s disease. Am J Gastroenterol 92:876–879

    PubMed  CAS  Google Scholar 

  48. Fellermman K, Ludwig D, Stahl M et al (1998) Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 93:1860–1866

    Article  Google Scholar 

  49. Sandborn WJ, Present DH, Isaacs KL et al (2003) Tacrolimus for the treatment of fistulae with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology 126:942–943

    Google Scholar 

  50. Gonzalez-Lama Y, Abreu L, Vera MI et al (2005) Longterm tacrolimus therapy in refractory to infliximab fistulizing Crohn’s disease: a pilot study. Inflamm Bowel Dis 11:8–15

    Article  PubMed  Google Scholar 

  51. Neurath MF, Wanitschke R, Peters M et al (1999) Randomized trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease. Gut 44:625–628

    Article  PubMed  CAS  Google Scholar 

  52. Fickert P, Hinterleitner TA, Wenzl HH et al (1998) Mycophenolate mofetil in patients with Crohn’s disease. Am J Gastroenterol 93:2529–2532

    Article  PubMed  CAS  Google Scholar 

  53. Miehsler W, Reinisch W, Moser G et al (2001) Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with active Crohn’s disease? Am J Gastroenterol 96:782–787

    Article  PubMed  CAS  Google Scholar 

  54. Fellermann K, Steffen M, Steinn J et al (2000) Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 14:171–176

    Article  PubMed  CAS  Google Scholar 

  55. Wenzl HH, Hinterleitneir TA, Aichbichler BW et al (2005) Mycophenolate mofetil for Crohn’s disease: short-term efficacy and long-term outcome. Aliment Pharmacol Ther 19:427–434

    Article  CAS  Google Scholar 

  56. Present DH, Rutgeerts P, Targann S et al (1999) Infliximab for the treatment of fistulae in patients with Crohn’s disease. N Engl J Med 340:1398–1405

    Article  PubMed  CAS  Google Scholar 

  57. Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549

    Article  PubMed  CAS  Google Scholar 

  58. Sands E, Anderson FH, Bernstein CN, Chey WY et al (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Eng J Med 350:876–885

    Article  CAS  Google Scholar 

  59. Hanauer SB (2005) Infliximab: lifetime use for maintenance is appropriate in Chron’s disease. CON: “lifetime use” is an awfully long time. Am J Gastroenterol 100:1435–1437

    Article  Google Scholar 

  60. Rutgeerts P, Feagna BG, Lichtenstein GR et al (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126:598–601

    Article  CAS  Google Scholar 

  61. Lichtenstein GR (2005) Infliximab: lifetime use for maintenance is appropriate in Crohn’s disease. Pro: maintenance therapy is superior to episodic therapy. Am J Gastroenterol 100:1433–1435

    Article  PubMed  Google Scholar 

  62. Poritz LS, Rowe WA, Koltun WA (2002) Remicade does not abolish the need for surgery in fistulizing Crohn’s disease. Dis Colon Rectum 45:771–775

    Article  PubMed  Google Scholar 

  63. Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr (2001) Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology 120:1640–1656

    Article  PubMed  CAS  Google Scholar 

  64. Lichtenstein GR, Yan S, Bala M et al (2005) Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology 128:862–869

    Article  PubMed  CAS  Google Scholar 

  65. Sandborn WJ, Feagan BG, Hanauer SB et al (2001) An engineered human antibody to TNF (CDP571) for active Crohn’s disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120:1330–1338

    Article  PubMed  CAS  Google Scholar 

  66. Eherenpreis ED, Kane SV, Cohen LB et al (1999) Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial. Gastroenterology 117:1271–1277

    Article  Google Scholar 

  67. Vasiliauskas EA, Kam Ly, Abreu-Martin MT et al (1999) An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn’s disease. Gastroenterology 117:1278–1287

    Article  PubMed  CAS  Google Scholar 

  68. Present DH (2003) Crohn’s fistula: current concepts in management. Gastroenterology 124:1629–1635

    Article  PubMed  Google Scholar 

  69. Calam J, Crooks PE, Walker RJ (1980) Elemental diets in the management of Crohn’s perianal fistulae. JPEN 4:4–8

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical and Surgical Sciences, Division of Gastroenterology, Policlinico “G.B. Rossi”, Verona, Italy

    Luigi Benini, Fosca De Iorio, Naika Tacchella & Italo Vantini

Authors
  1. Luigi Benini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fosca De Iorio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naika Tacchella
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Italo Vantini
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgery and Gastroenterology, University of Verona, Verona, Italy

    Gian Gaetano Delaini

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Italia

About this chapter

Cite this chapter

Benini, L., De Iorio, F., Tacchella, N., Vantini, I. (2006). Medical Therapy of Fistulizing Crohn’s Disease. In: Delaini, G.G. (eds) Inflammatory Bowel Disease and Familial Adenomatous Polyposis. Springer, Milano. https://doi.org/10.1007/88-470-0434-9_17

Download citation

  • DOI: https://doi.org/10.1007/88-470-0434-9_17

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0433-7

  • Online ISBN: 978-88-470-0434-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation